Interpreting important health-related quality of life change using the Haem-A-QoL

Haemophilia

Volumn 21, Issue 5, 2015, Pages 578-584

  Wyrwich, K W ^a   Krishnan, S ^b   Poon, J L ^a   Auguste, P ^a   von Maltzahn, R ^a   Yu, R ^a   von Mackensen, S ^c  

^a EVIDERA   (United States)

^b BIOGEN   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Clinical trial; Haem A QoL; Haemophilia; Minimal clinically important difference; Quality of life; Responder definition

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; HAEMOPHILIA QUALITY OF LIFE QUESTIONNAIRE FOR ADULT; HEALTH STATUS; HEMOPHILIA A; HEMOPHILIA B; HUMAN; LEISURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SPORT; ADOLESCENT; AGED; HEALTH; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; HEALTH; HEMOPHILIA A; HUMANS; LEISURE ACTIVITIES; MIDDLE AGED; QUALITY OF LIFE; SPORTS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84942192012     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12642     Document Type: Article

References (21)

1. Von Mackensen S. Quality of life and sports activities in patients with haemophilia. Haemophilia 2007; 13 Suppl 2: 38-43.
2. von Mackensen S, Scalone L, Ravera S, Mantovani L, Gringeri A, The COCHE Study Group. Assessment of health-related quality of life in patients with haemophilia with the newly developed haemophilia-specific instrument (Haem-A-QoL). Value Health 2005; 8: A127.
3. Wyrwich KW, Auguste P, von Maltzahn R, Yu R, Krishnan S, Dodd N et al. Psychometric evaluation of health-related quality of life assessments from the A-LONG and B-LONG hemophilia clinical trials. Blood 2013a; 122: 423.
4. Santagostino E, Lentz SR, Busk AK, Regnault A, Iorio A. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia 2014; 20: 527-34.
5. Guyatt G, Schunemann H. How can quality of life researchers make their work more useful to health workers and their patients? Quality Life Res. 2007; 16: 1097-105.
6. Wyrwich KW, Norquist JM, Lenderking WR, Acaster S, Industry Advisory Committee of International Society for Quality of Life R. Methods for interpreting change over time in patient-reported outcome measures. Quality Life Res. 2013; 22: 475-83.
7. Food and Drug Administration. Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Reg 2009; 74: 65132-3.
8. Wyrwich KW, Bullinger M, Aaronson N, Hays RD, Patrick DL, Symonds T et al. Estimating clinically significant differences in quality of life outcomes. Quality Life Res. 2005; 14: 285-95.
9. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J. Pain 2008; 9: 105-21.
10. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 2008; 61: 102-9.
11. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25.
12. Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. New Engl J Med 2013; 369: 2313-23.
13. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199-208.
14. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol 1999a; 52: 861-73.
15. Wyrwich KW, Nienaber NA, Tierney WM, Wolinsky FD. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care 1999b; 37: 469-78.
16. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003; 41: 582-92.
17. Norman GR. The relation between the minimally important difference and patient benefit. Copd 2005; 2: 69-73.
18. Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR, Clinical Significance Consensus Meeting G. Methods to explain the clinical significance of health status measures. Mayo Clinic Proc. 2002; 77: 371-83.
19. Leidy NK, Wyrwich KW. Bridging the gap: using triangulation methodology to estimate minimal clinically important differences (MCIDs). Copd 2005; 2: 157-65.
20. Wyrwich KW, Krishnan S, Auguste P, Von Maltzahn R, Yu R, Bozkaya D et al. Health-related quality of life data changes from baseline using Haem-A-QoL scores in the A-LONG clinical study of recombinant factor VIII Fc fusion protein. Haemophilia 2014a; 20: 169.
21. Wyrwich KW, Krishnan S, Auguste P, Von Maltzahn R, Yu R, Bozkaya D et al. Health-related quality of life data changes over time using Haem-A-QoL scores in the B-LONG clinical study of recombinant factor IX Fc fusion protein. Haemophilia 2014b; 20: 173.